On November 4, 2016, Keith A. Goldan, the Fibrocell Science, Inc.'s Chief Financial Officer, provided notice of his intention to resign from the company. On the same date, the company and Mr. Goldan entered into a Separation Agreement and Release. Pursuant to the terms of the Separation Agreement and Release: the effective date of Mr. Goldan's resignation will be January 1, 2017. Mr. Goldan will continue to serve as Chief Financial Officer and support the transition of his roles and responsibilities until January 1, 2017. On November 7, 2016, the Company appointed Kimberly Smith to serve as the Company's principal accounting officer. Ms. Smith joined the Company in 2014 as the Company's Controller. From October 2014 to March 2015, Ms. Smith served as the Company's interim Chief Financial Officer, Treasurer and Corporate Secretary and since March 2016, as the Company's Vice President of Corporate Accounting/Controller. Prior to joining the Company, Ms. Smith was a financial consultant with AC Lordi Corporation from 2010 to 2013 working exclusively for AC Lordi Corporation's client, ViroPharma Incorporated.